DekaBank Deutsche Girozentrale
PGNX

DekaBank Deutsche Girozentrale’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-21,500
Closed -$113K – 1264
2019
Q3 		$113K Sell
21,500
-21,500
-50% -$107K ﹤0.01% 904
2019
Q2 		$250K Buy
43,000
+16,500
+62% +$79.6K ﹤0.01% 996
2019
Q1 		$208K Buy
26,500
+5,000
+23% +$22.6K ﹤0.01% 1036
2018
Q4 		$84K Sell
21,500
-5,000
-19% -$25.5K ﹤0.01% 1087
2018
Q3 		$208K Sell
26,500
-500
-2% -$3.84K ﹤0.01% 1058
2018
Q2 		$219K Buy
27,000
+18,000
+200% +$137K ﹤0.01% 1034
2018
Q1 		$66K Hold
9,000
– – ﹤0.01% 1074
2017
Q4 		$52K Hold
9,000
– – ﹤0.01% 1016
2017
Q3 		$52K Hold
9,000
– – ﹤0.01% 1024
2017
Q2 		$63K Hold
9,000
– – ﹤0.01% 995
2017
Q1 		$86K Sell
9,000
-1,000
-10% -$9.98K ﹤0.01% 916
2016
Q4 		$90K Buy
+10,000
New +$73.9K ﹤0.01% 928
2016
Q2 		– Sell
-34,500
Closed -$147K – 1077
2016
Q1 		$147K Sell
34,500
-1,000
-3% -$4.45K ﹤0.01% 898
2015
Q4 		$221K Buy
35,500
+500
+1% +$3.28K ﹤0.01% 846
2015
Q3 		$200K Buy
35,000
+1,000
+3% +$7.67K ﹤0.01% 870
2015
Q2 		$254K Buy
34,000
+1,500
+5% +$9.07K ﹤0.01% 832
2015
Q1 		$194K Sell
32,500
-5,000
-13% -$31.5K ﹤0.01% 914
2014
Q4 		$271K Sell
37,500
-3,000
-7% -$17.9K ﹤0.01% 811
2014
Q3 		$210K Buy
40,500
+500
+1% +$2.49K ﹤0.01% 803
2014
Q2 		$172K Buy
40,000
+4,500
+13% +$17.2K ﹤0.01% 770
2014
Q1 		$145K Buy
35,500
+1,000
+3% +$5.11K ﹤0.01% 762
2013
Q4 		$189K Buy
34,500
+1,000
+3% +$4.4K ﹤0.01% 672
2013
Q3 		$169K Buy
+33,500
New +$182K ﹤0.01% 684

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DekaBank Deutsche Girozentrale's PGNX Position: Q4 2019 in Review

DekaBank Deutsche Girozentrale sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 21,500 shares — an estimated $113K sold.

DekaBank Deutsche Girozentrale first reported a position in PGNX in Q3 2013 and held it in 23 quarters. The position peaked at $271K in Q4 2014. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • DekaBank Deutsche Girozentrale reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 21,500 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $113K.
  • DekaBank Deutsche Girozentrale first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 23 quarters.
  • DekaBank Deutsche Girozentrale's Progenics Pharmaceuticals Inc position peaked at $271K in Q4 2014.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2019, filed 4 Feb 2020.